Tumor News and Research

RSS

Researchers develop protein therapy that may stop cancer growth

A team of Stanford researchers has developed a protein therapy that disrupts the process that causes cancer cells to break away from original tumor sites, travel through the blood stream and start aggressive new growths elsewhere in the body.

22 Sep 2014

Curcumin, cancer-inhibiting peptides show promise in slowing progression of mesothelioma

A common Asian spice and cancer-hampering molecules show promise in slowing the progression of mesothelioma, a cancer of the lung's lining often linked to asbestos. Scientists from Case Western Reserve University and the Georg-Speyer-Haus in Frankfurt, Germany, demonstrate that application of curcumin, a derivative of the spice turmeric, and cancer-inhibiting peptides increase levels of a protein inhibitor known to combat the progression of this cancer.

22 Sep 2014

Longer looks: Lithium in the water; controlling cancer; recovering from brain injury

There are many kinds of cancer, but treatments have typically combatted them in one way only: by attempting to destroy the cancerous cells. Surgery aims to remove the entire growth from the body; chemotherapy drugs are toxic to the cancer cells; radiation generates toxic molecules that break up the cancer cells' DNA and proteins, causing their demise.

19 Sep 2014

LSU Health researchers reveal how Chop plays crucial role to combat cancer

Research led by Paulo Rodriguez, PhD, an assistant research professor of Microbiology, Immunology & Parasitology at LSU Health New Orleans' Stanley S. Scott Cancer Center, has identified the crucial role an inflammatory protein known as Chop plays in the body's ability to fight cancer.

19 Sep 2014

Exercise may have added benefit for cancer patients undergoing chemotherapy: Study

Study after study has proven it true: exercise is good for you. But new research from University of Pennsylvania scientists suggests that exercise may have an added benefit for cancer patients undergoing chemotherapy.

19 Sep 2014

Penn Medicine, Wistar Institute awarded NCI grants for four new melanoma research projects

Penn Medicine and The Wistar Institute have been awarded a prestigious $12.1 million SPORE grant from the National Cancer Institute. The five-year Specialized Programs of Research Excellence, or SPORE, grant will fund four new melanoma research projects that aim to translate fundamental laboratory discoveries into new therapeutics to treat melanoma and other skin cancers.

18 Sep 2014

ICO-IDIBELL researchers identify 5 genes differentially expressed in colorectal tumors

Researchers at the Catalan Institute of Oncology-Bellvitge Biomedical Research Institute, led by David Garcia-Mollev- have identified 5 genes differentially expressed in normal accompanying cells in colorectal tumors.

17 Sep 2014

Radiation and endocrine therapy combination may not be necessary for all HR+ breast cancer patients

Treatment with endocrine therapy and radiation therapy as part of breast conservation is the current standard of care for women with hormone-receptor positive (HR+) invasive breast cancer. A new study by researchers at Fox Chase Cancer Center, however, shows that combination may not be necessary for all patient populations with the disease.

17 Sep 2014

Current smokers at increased risk of developing SPLC

Non-small cell lung cancer (NSCLC) survivors who never smoked or who are former smokers at the time of diagnosis have a lower risk of developing secondary primary lung cancers (SPLC) compared to those who are current smokers, suggesting that increased tobacco exposure is associated with a higher risk of SPLC, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.

17 Sep 2014

EnGeneIC receives award from Cancer Institute NSW for groundbreaking cancer research

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, announced that, together with the Asbestos Disease Research Institute, it has received the 2014 Cancer Institute New South Wales Premier’s Award for Excellence in Translational Cancer Research.

17 Sep 2014

3D-printed heart model created by Materialise

Materialise (Nasdaq:MTLS), a pioneer in 3D Printing for medical applications, recently created a 3D-printed heart model for doctors at Cincinnati Children’s Hospital to support Bradley White’s case, a 16-year-old boy who was born with a tumor. With the aid of Materialise’s HeartPrint® 3D-printed model, his doctors were able to determine the best treatment for Bradley’s erratic heartbeat.

From Materialise 17 Sep 2014

UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults.

17 Sep 2014

Zebrafish may hold key to unlocking a leading cause of respiratory diseases

A small freshwater fish found in many tropical aquariums may hold the key to unlocking one of the leading causes of respiratory diseases in humans.

17 Sep 2014

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I).

17 Sep 2014

Denovo gains all rights from Lilly to develop, manufacture and commercialize enzastaurin drug

Denovo Biopharma, LLC, today announced that it has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company. Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data, and information.

16 Sep 2014

Scientists develop new method to get clearer picture of how drug abuse affects the brain

One thing leads to another, especially in research. When Stony Brook University School of Medicine scientists developed a new method to measure how cocaine disrupts blood flow in the brains of mice, doctors and researchers got a way to form a clearer picture of how drug abuse affects the brain.

16 Sep 2014

Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

A blood test may be beneficial in indicating neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma (ESCC), according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.

16 Sep 2014

RT alone effective in decreasing dysphagia in patients with advanced esophageal cancer

Radiation therapy (RT) alone is as effective in decreasing swallowing complications experienced by advanced esophageal cancer patients as RT combined with chemotherapy, thus allowing patients to forgo chemotherapy, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.

16 Sep 2014

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds.

16 Sep 2014

Collaborative study takes important step toward finding targeted treatments for bladder cancer

The story of cancer care seems so simple: find the mutated gene that causes cancer and turn it off or fix it. But rarely does a single gene cause cancer. More often, many genes are altered together to drive the disease. So the challenge becomes sorting out which altered genes are the most to blame in which cancers.

16 Sep 2014

Tumor News and Research

Researchers develop protein therapy that may stop cancer growth

Curcumin, cancer-inhibiting peptides show promise in slowing progression of mesothelioma

Longer looks: Lithium in the water; controlling cancer; recovering from brain injury

LSU Health researchers reveal how Chop plays crucial role to combat cancer

Exercise may have added benefit for cancer patients undergoing chemotherapy: Study

Penn Medicine, Wistar Institute awarded NCI grants for four new melanoma research projects

ICO-IDIBELL researchers identify 5 genes differentially expressed in colorectal tumors

Radiation and endocrine therapy combination may not be necessary for all HR+ breast cancer patients

Current smokers at increased risk of developing SPLC

EnGeneIC receives award from Cancer Institute NSW for groundbreaking cancer research

3D-printed heart model created by Materialise

UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

Zebrafish may hold key to unlocking a leading cause of respiratory diseases

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

Denovo gains all rights from Lilly to develop, manufacture and commercialize enzastaurin drug

Scientists develop new method to get clearer picture of how drug abuse affects the brain

Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

RT alone effective in decreasing dysphagia in patients with advanced esophageal cancer

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Collaborative study takes important step toward finding targeted treatments for bladder cancer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News